YOLFTbeta
Theravance Biopharma Inc

Theravance Biopharma Inc

TBPH · NASDAQ · Healthcare / Biotechnology

17.03USD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close17.03
Open17.03
Day Range17.03 – 17.03
52-Week Range13.08 – 21.03
Volume0
Market Cap884.18M
P/E (TTM)16.38
Forward P/E9.73
EPS1.04
Dividend Yield0.00%
Beta0.24
50-Day Avg16.96
200-Day Avg17.18

About

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Rick E. Winningham M.B.A.
  • Employees90
  • Headquarters901 Gateway Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.theravance.com

Leadership

  • Mr. Rick E. Winningham M.B.A.CEO & Director · b. 1960
  • Ms. Rhonda F. FarnumChief Business Officer and Senior VP of Commercial & Medical Affairs · b. 1965
  • Dr. Aine Miller Ph.D.Senior VP of Development & Head of Ireland Office · b. 1977
  • Mr. Aziz Sawaf C.F.A.Senior VP of Operations Strategy & CFO · b. 1982
  • Mr. Stuart KnightSenior VP of IT&I and Chief Information Officer
  • Mr. Brett A. Grimaud Esq.Senior VP, General Counsel & Secretary · b. 1974
  • Ms. Stacy L. PryceSenior VP & Chief Strategy Officer

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue14.85M130.15M226.00K11.69M42.13M48.65M15.39M60.37M73.41M71.86M55.31M51.35M57.42M64.38M107.46M
Growth (%)-+776.16%-99.83%+5071.68%+260.42%+15.48%-68.37%+292.37%+21.61%-2.12%-23.03%-7.17%+11.84%+12.12%+66.92%
Cost of Revenue3.84M114.00M120.58M4.06M4.66M2.89M6.03M715.00K219.25M260.95M193.66M63.39M40.62M37.64M5.51M
Gross Profit11.01M16.15M-120.35M7.63M37.47M45.75M9.36M59.66M73.41M71.86M-138.35M-12.05M16.80M26.74M101.95M
Gross Margin74.12%12.41%-53253.54%65.28%88.95%94.05%60.81%98.82%100.00%100.00%-250.12%-23.46%29.26%41.53%94.87%
Operating Expense120.34M25.73M35.93M240.17M219.37M226.22M269.48M298.41M325.33M369.48M119.44M79.91M72.84M73.69M115.19M
Operating Income-109.33M-9.57M-156.28M-232.54M-181.90M-180.47M-260.12M-238.75M-251.91M-297.63M-257.78M-91.96M-56.03M-46.95M-13.25M
Operating Margin-736.06%-7.36%-69152.21%-1989.55%-431.80%-370.96%-1690.65%-395.48%-343.14%-414.19%-466.06%-179.09%-97.58%-72.92%-12.33%
EBITDA-105.49M-6.32M-153.63M-229.88M-178.77M-176.04M-259.14M-212.44M-203.60M-287.82M-232.83M-76.08M-51.65M-38.45M137.22M
EBITDA Margin-710.19%-4.86%-67978.32%-1966.78%-424.37%-361.86%-1684.24%-351.89%-277.33%-400.55%-420.95%-148.18%-89.94%-59.73%127.69%
Net Income-109.33M-9.57M-156.28M-237.04M-182.22M-190.67M-285.40M-215.52M-236.46M-278.02M-199.43M872.13M-55.19M-56.42M105.89M
Net Income Margin-736.06%-7.36%-69152.21%-2028.05%-432.56%-391.94%-1854.97%-357.01%-322.08%-386.90%-360.55%1698.54%-96.11%-87.63%98.54%
R&D98.85M114.00M120.58M168.52M129.16M141.71M173.89M201.35M219.25M260.95M201.55M70.07M46.34M38.05M37.41M
R&D as % of Total Revenue665.48%87.59%53353.54%1441.84%306.62%291.30%1130.16%333.52%298.65%363.16%364.39%136.47%80.70%59.10%34.82%
Interest Expense-001.86M631.00K1.40M8.55M10.48M31.86M8.55M8.55M6.37M2.35M2.55M2.46M
Interest Expense % of Total Revenue-0.00%0.00%15.96%1.50%2.89%55.55%17.36%43.40%11.89%15.45%12.40%4.09%3.95%2.29%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets13.82M20.96M25.18M337.77M300.12M639.25M441.40M560.24M408.83M469.06M374.82M607.40M382.00M354.16M485.57M
Total Liabilities154.54M22.67M42.21M47.98M57.05M289.02M326.22M611.82M632.67M772.81M713.39M165.60M169.00M178.62M188.85M
Total Equity-140.72M-6.99M-17.04M289.79M243.06M350.23M115.18M-51.59M-223.84M-303.75M-338.57M441.80M213.00M175.54M296.72M
Cash--89.00M89.22M112.71M344.71M88.98M378.02M58.06M81.47M89.96M298.17M39.55M37.80M167.81M
Total Debt69.00K----222.68M223.75M454.35M510.53M676.26M669.52M52.16M49.16M49.82M75.50M
Net Debt69.00K---89.22M-112.71M-122.03M134.77M76.33M452.46M594.79M579.56M-246.01M9.61M12.02M-92.31M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-83.43M-119.11M-120.96M-175.16M-168.86M-98.99M-201.05M-112.87M-238.20M-250.40M-207.86M-186.99M-27.00M-11.54M238.54M
Investing Cash Flow-3.05M-2.43M-2.63M-106.25M111.04M-148.24M-56.33M176.71M-83.05M10.72M124.49M1.15B-32.70M12.28M-105.28M
Financing Cash Flow86.48M121.54M123.59M370.62M81.31M479.23M1.66M225.20M1.29M263.08M91.86M-758.81M-198.93M-2.50M-3.25M
Capital Expenditure3.63M2.59M2.73M3.11M2.65M2.13M2.41M7.24M3.18M6.62M3.41M572.00K2.49M332.00K42.00K
Free Cash Flow-87.06M-121.70M-123.69M-178.26M-171.50M-101.12M-203.46M-120.11M-241.37M-257.02M-211.26M-187.56M-29.48M-11.87M238.50M
Dividends Paid---0000--385.06M-802.00K---
FCF to OCF104.35%102.17%102.26%101.77%101.57%102.16%101.20%106.41%101.33%102.64%101.64%100.31%109.22%102.88%99.98%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%---149.82%--0.43%---

Earnings

Report DateAug 13, 2014Nov 6, 2014Mar 10, 2015May 7, 2015Aug 10, 2015Nov 9, 2015Mar 9, 2016May 9, 2016Aug 8, 2016Nov 8, 2016Feb 27, 2017May 9, 2017Aug 8, 2017Nov 7, 2017Feb 27, 2018May 8, 2018Aug 1, 2018Nov 6, 2018Feb 26, 2019May 7, 2019Jul 31, 2019Nov 5, 2019Feb 24, 2020May 6, 2020Aug 6, 2020Nov 5, 2020Feb 23, 2021May 4, 2021Aug 3, 2021Nov 3, 2021Feb 23, 2022May 5, 2022Aug 8, 2022Nov 7, 2022Feb 27, 2023May 8, 2023Aug 7, 2023Nov 7, 2023Feb 26, 2024May 13, 2024Aug 5, 2024Nov 12, 2024Feb 24, 2025May 8, 2025Aug 12, 2025Nov 10, 2025Mar 4, 2026May 7, 2026Aug 10, 2026Nov 9, 2026
EPS Estimate-0.46-1.85-1.70-1.31-1.51-1.55-1.61-0.97-1.00-0.87-1.05-1.18-1.17-1.14-1.16-1.36-1.23-1.14-1.06-1.19-1.24-1.11-1.13-1.00-0.88-0.88-1.02-0.79-0.88-0.52-0.330.100.15-0.04-0.17-0.20-0.11-0.09-0.15-0.12-0.07-0.10-0.08-0.090.67-0.051.000.090.140.19
EPS Actual-1.83-1.72-2.02-1.29-1.42-1.40-1.23-1.10-1.06-0.73-1.36-1.27-1.27-1.27-1.64-1.22-0.76-1.10-0.92-1.32-0.72-1.05-1.17-1.14-1.00-1.16-0.92-1.24-0.80-0.46-0.43-0.220.09-0.10-0.15-0.24-0.13-0.010.03-0.09-0.13-0.06-0.05-0.171.080.040.060.010.07-
Surprise-297.83%7.03%-18.82%1.53%5.96%9.68%23.60%-13.40%-6.00%16.09%-29.52%-7.63%-8.55%-11.40%-41.38%10.29%38.21%3.51%13.21%-10.92%41.94%5.41%-3.54%-14.00%-13.64%-31.82%9.80%-56.96%9.09%11.54%-30.30%-320.00%-40.00%-150.00%11.76%-20.00%-18.18%88.89%120.00%25.00%-85.71%40.00%39.86%-88.89%61.19%180.00%-94.10%-88.89%-50.00%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap884.18M
Enterprise Value535.09M
Trailing P/E16.38
Forward P/E9.73
PEG Ratio-0.05
Price / Sales8.48
Price / Book3.05
EPS1.04
Book Value5.58
Revenue (TTM)104.31M
Gross Profit (TTM)78.30M
EBITDA11.10M
Profit Margin51.58%
Operating Margin8.89%
Return on Equity20.91%
Return on Assets1.33%
Shares Outstanding51.92M
Shares Float25.87M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 17.67
  • Strong Buy
    1
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
94.71%
Insiders
4.61%
Retail / Other
0.68%

Top Institutional Holders

  • Madison Avenue Partners, LP
    9.51M18.32%
  • Weiss Asset Management LP
    7.46M14.36%
  • Newtyn Management LLC
    4.84M9.33%
  • BlackRock Inc
    4.30M8.28%
  • Irenic Capital Management LP
    2.76M5.32%
  • Vanguard Capital Management, LLC
    1.78M3.44%
  • State Street Corp
    1.30M2.50%
  • Acadian Asset Management LLC
    1.28M2.46%
  • Two Sigma Investments LLC
    1.23M2.36%
  • D. E. Shaw & Co LP
    1.19M2.28%
  • Geode Capital Management, LLC
    1.14M2.19%
  • Dimensional Fund Advisors, Inc.
    1.04M2.01%
  • UBS Group AG
    764.11K1.47%
  • Oasis Management Co. Ltd
    583.49K1.12%
  • Morgan Stanley - Brokerage Accounts
    510.27K0.98%
  • Citadel Advisors Llc
    506.67K0.98%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.30M2.50%
  • iShares Russell 2000 ETF
    1.04M1.99%
  • Canada Life US Small-Mid Cap Growth F
    441.41K0.85%
  • Fidelity Small Cap Index
    435.75K0.84%